Vir Biotechnology, Inc. today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) ...

An estimated 100 million Americans have some form of liver disease, yet only 4.5 million U.S. adults have received a formal ...

The new company has also raised $75 million that will support the development of epigenetic editing therapies for hepatitis B ...